Navigation Links
Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
Date:2/17/2009

Chugai Pharmaceutical Gains Rights to Develop and Market Nitazoxanide for the Treatment of Chronic Hepatitis C

TAMPA, Fla., Feb. 17 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, and Chugai Pharmaceutical Co. Ltd., a member of the Roche Group, today announced that the two companies have entered into an exclusive license agreement for the development and commercialization of nitazoxanide as a treatment of chronic hepatitis C in Japan.

Under the terms of the agreement, Chugai has paid an upfront payment to Romark, and will make additional payments based on the achievement of certain clinical and regulatory milestones. Romark will participate in profits from product sales in Japan through a supply agreement and royalties.

"Chugai is an excellent partner for us in Japan. They bring substantial expertise in the development and marketing of treatments for chronic hepatitis C exemplified by their experience with Pegasys(R) and Copegus(R)," said Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark Laboratories, and inventor of the thiazolides. "This agreement is an important step in accelerating the worldwide development and commercialization of nitazoxanide for treating this disease."

Tatsuro Kosaka, Senior Vice President, Head of Lifecycle Management & Marketing Unit of Chugai Pharmaceutical said, "We believe nitazoxanide will be an important addition to current and future treatment regimens for chronic hepatitis C. This agreement demonstrates our commitment to providing innovative new treatments for chronic hepatitis C in Japan."

About Nitazoxanide and Hepatitis C

Nitazoxanide, the first of a new class of broad spectrum antiviral drugs known as the thiazolides, is undergoing worldwide development as a treatment of chronic hepatitis C. Nitazoxanide is a potent inhibitor of hepatitis C virus (HC
'/>"/>

SOURCE Romark Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
3. Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco
4. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008
5. Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn ... biotechnology company, Syngenta, are in the process of being ... The consolidated case is In Re: Syngenta AG MIR ... District Court for the District of Kansas. , Management ... been handed over to U.S. District Judge John W. ...
(Date:12/24/2014)... The report provides basic ... definition, classification, application and industry overview. This ... and product cost structure. Production is separated ... also covers upstream raw materials, equipment, downstream ... and proposals. In the end, the export ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
(Date:12/22/2014)... PA & Brussels (PRWEB) December 22, 2014 ... (CfPIE), the global leader of technical training across ... Society for Clinical Data Management (SCDM) to provide ... and certification programs —providing access to the more ... partnership extends SCDM members with 10% off when registering ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... spotlight on the,ever-growing field of life sciences, Larta Institute,s ... in the midst of the dark backdrop of the,current ... to,focus on brilliant entrepreneurs in the life sciences, even ... years, through good,economic times and bad, the passion and ...
... 14 Access Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) announced ... & Renshaw 5th Annual Global Healthcare Conference to be ... in Monte Carlo, Monaco.,Jeffrey B. Davis, CEO of Access ... 3:10 pm local time, 9:10 am Eastern time and ...
... May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... has,received a letter of approval from the ... for its Clinical Trial Application (CTA),to begin ... administration of,REOLYSIN(R) in combination with paclitaxel and ...
Cached Biology Technology:Betting on Change - The Venture Forum in 2008 2Betting on Change - The Venture Forum in 2008 3Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 2Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2
(Date:12/11/2014)... 10, 2014  That blood pressure plays a role in ... – the medical term for high blood pressure – was ... the inflatable cuff that,s used in measuring blood pressure was ... nothing new about hypertension, its triggers and its effects. In ... condition and the best ways to treat it. ...
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... New knowledge points to the fact that a genetically ... skin barrier, plays a decisive role in the origin ... 3000 school-children scientists of the Helmholtz Zentrum Mnchen and ... the German population carry variations of the filaggrin gene, ...
... (MS), neuroradiologists and neurologists of the University hospitals of ... tissue damage, most of which had remained unrecognized up ... medium, Gadofluorine M, in magnetic resonance imaging. The scientists ... the renowned medical journal Brain . ...
... , Now that Olympia is approaching, the Chinese authorities ... large cities with different measures. For example, the car ... ordered not to use 70 percent of all company ... even or odd days - in accordance with their ...
Cached Biology News:When our protective armor shows weakness 2Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model 2GKSS membranes reduce air pollution in Beijing 2
... host strains are K-12 derivatives that have ... and glutathione reductase (gor) genes, which greatly ... Studies have shown that expression in Origami(DE3) ... another host even though overall expression levels ...
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... Kit, 1 kit. Convenient way ... Conjugations are carried out under mild ... Dyes are packaged in premeasured amounts ... Category: Blotting & Labeling & Detection, ...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Biology Products: